7 Best Peptides for Leaky Gut

What to Know Before Choosing a Peptide for Leaky Gut

Leaky gut, formally called intestinal hyperpermeability, is a condition where the tight junctions between intestinal cells loosen, allowing bacteria, toxins, and undigested particles to cross into the bloodstream. That crossing triggers a cascade of systemic inflammation that shows up as everything from bloating and food sensitivities to autoimmune flares and metabolic disruption. People who have spent any time researching it quickly discover that there is not one single driver and not one single fix, which is exactly why this goal draws a wider field of compounds than almost any other in the peptide world.

A peptide earned a slot on this list because people use it for leaky gut or are actively discussing using it. That is the whole filter. FDA-approved compounds, research chemicals accessed through telehealth and compounding pharmacies, and compounds used in community protocols without a formal approval pathway are all eligible, and all are represented here. Evidence strength is stated honestly inside each entry rather than used as a gate for inclusion. Some compounds have human clinical trial data. Some have only animal research. Some rest primarily on user-reported experience. All of them are named because omitting a widely-used compound to protect the list from thin evidence would leave the reader with an incomplete map of the field.

The compounds are numbered by how prominently each appears in research and documented real-world use, not as a ranking of one being better than another for your situation. Number one is not a recommendation. Number seven is not a consolation. The order reflects which compounds have accumulated the most discussion, the deepest research attention, or the most consistent user-reported use for this specific goal. The right compound for any individual depends on what is driving their gut permeability, their health history, and what they put together with the MyPeptidePal app.

One practical note before getting into the entries: with the exception of GLP-2, none of the compounds covered here are FDA-approved for leaky gut. Access runs through compounding pharmacies under physician supervision or through the research-chemical market, and those two pathways carry very different quality and safety considerations. That reality does not change which compounds belong on this list, but it is worth understanding before you read further.

1. BPC-157: For Structural Repair of the Intestinal Lining

BPC-157, short for Body Protection Compound-157, is a 15-amino-acid peptide derived from a protein found in human gastric juice. It holds the top position on this list because no other peptide combines its volume of gut-specific research, its breadth of use in community protocols, and the practical advantage of working by mouth, which matters enormously when the goal is healing the intestinal lining directly.

The mechanism most relevant to leaky gut is tight junction preservation. Animal studies show that BPC-157 protects and helps restore the proteins that seal the gaps between intestinal epithelial cells, specifically ZO-1 and occludin, which are the structural building blocks of tight junctions. When NSAID use, inflammation, or chronic stress degrades those proteins and opens the barrier, BPC-157 appears to signal the tissue to rebuild. It also promotes the growth of new blood vessels in damaged tissue, a process called angiogenesis, which improves delivery of nutrients and immune resources to the area that needs repair. On top of that, it stimulates collagen synthesis and growth factor expression, both part of the physical scaffolding the gut wall depends on.

The honest account of the evidence is this: every piece of formal GI research on BPC-157 comes from animal models. No published human clinical trial has tested it specifically for leaky gut or intestinal permeability as of 2026. That is a significant gap. It is also the gap that makes community-reported experience important to understand here. Across forums and functional medicine practices, BPC-157 is the most frequently discussed peptide for leaky gut by a wide margin. Users report reduced bloating, less GI pain, improved tolerance of previously problematic foods, and significant symptom reduction in conditions like IBS-C, SIBO, and histamine intolerance. Those reports are not clinical data, but their consistency and volume are part of why this compound sits at the top of the list.

One feature that sets BPC-157 apart from almost every other peptide is its stability in stomach acid. Most peptides are broken down before they ever reach the intestinal lining. BPC-157 survives that environment, which means oral capsule delivery is a genuinely viable route for gut-specific applications, not a lesser substitute for injection. Functional medicine practitioners who use it for leaky gut often prefer the oral route for exactly this reason: the compound reaches the tissue it is meant to heal without requiring systemic delivery first. Injectable BPC-157 is also used, and tends to be preferred when systemic effects are the goal, but for isolated gut applications the oral path is considered more appropriate. Two notes worth flagging: BPC-157 is banned by the World Anti-Doping Agency, which matters for competitive athletes, and it is contraindicated in anyone with a history of cancer because its angiogenic effects could theoretically promote tumor growth.

2. KPV: For Calming the Inflammatory Driver

KPV is a tripeptide fragment, three amino acids in sequence, lysine-proline-valine, cleaved from the C-terminal end of alpha-melanocyte-stimulating hormone. It is not a structural repair compound in the way BPC-157 is. Its strength is specifically anti-inflammatory, and that distinction matters for how it gets used.

The mechanism that makes KPV relevant to leaky gut runs through NF-kB, the central signaling switch that drives pro-inflammatory cytokine production. When bacterial toxins cross a leaky barrier and activate the immune cascade, NF-kB is the hub that amplifies the inflammatory response. KPV inhibits that hub, and it does so with an unusual degree of specificity to inflamed bowel tissue. It reaches the intestinal lining via a transporter protein called PepT1, which concentrates the compound exactly where the inflammation is highest rather than distributing it systemically. In addition to quieting the inflammatory response, KPV appears to enhance epithelial barrier function and help seal tight junctions, though that action is secondary to its anti-inflammatory effect.

The evidence base for KPV is preclinical as of 2026. Human data remains limited, and the research is ongoing. What exists is early-stage work showing its anti-inflammatory mechanism and its PepT1-mediated concentration in inflamed bowel tissue, which is a meaningful finding even at the preclinical stage because it explains why practitioners pair it specifically with BPC-157 rather than treating the two as interchangeable. The logic of the combination is straightforward: BPC-157 handles the structural work of rebuilding the barrier, and KPV handles the immune overactivation that would otherwise continue damaging it. Addressing both simultaneously is the rationale behind the most common functional medicine protocol for leaky gut.

KPV is accessed through compounding pharmacies under physician supervision. It is discussed in functional medicine circles more than in general community peptide forums, partly because its use case is specific and partly because it is typically prescribed as part of a supervised protocol rather than self-administered.

3. Larazotide Acetate: For Targeting the Leaky Junction Directly

Larazotide acetate, also referred to in clinical trial literature as AT-1001 and informally as "Lorazide" in some user communities, holds a unique position in this field. It is the only compound on this list specifically designed to address the mechanism of leaky gut at its source, which is the zonulin pathway.

Zonulin is a protein that signals tight junctions to loosen and open. Elevated zonulin levels appear in celiac disease, gluten sensitivity, and a range of conditions associated with intestinal hyperpermeability. Larazotide acts as a direct zonulin antagonist: it binds to zonulin receptors and blocks the loosening signal before it can open the junctions. Where BPC-157 repairs damaged tissue after the fact and KPV quiets the immune response downstream, Larazotide intervenes at the very first step, preventing the translocation of bacterial toxins into systemic circulation by keeping the barrier closed.

This mechanistic precision is backed by something rare in this field: human clinical trials. Larazotide has been studied in registered clinical trials examining its effects on gut barrier integrity and celiac disease management. It is not FDA-approved, including for celiac disease, and it remains investigational. User-reported experience is thinner than BPC-157's, partly because access is less straightforward. People who have used it, primarily in the context of celiac disease and gluten sensitivity, describe it as helpful for sealing the gut, with some reporting meaningful symptom improvement over several weeks. Practitioners sometimes describe it as a compound to consider "when clinically available," which suggests that accessibility remains an active limitation even as its underlying science is more developed than many of its peers.

For anyone whose leaky gut has a strong gluten-sensitivity or celiac component, Larazotide is worth understanding. Its mechanism is the most targeted on this list relative to the specific biology of tight junction regulation.

4. GLP-2: The Only FDA-Approved Gut Lining Option

GLP-2, glucagon-like peptide-2, is an endogenous gut peptide that the intestinal lining produces naturally in response to food. The synthetic version, teduglutide, sold under the name Gattex, is the only compound in this field that carries FDA approval and large human clinical trial data supporting its effects on intestinal integrity.

The caveat matters: GLP-2 is approved for short bowel syndrome, a specific condition involving severe intestinal failure, not for leaky gut or intestinal hyperpermeability as those terms are commonly used. Its mechanism is directly relevant to gut barrier health: it promotes the growth and maintenance of intestinal epithelial cells, supports mucosal barrier function, and helps sustain the physical lining of the gut wall. These actions overlap with what people are trying to achieve when treating leaky gut, even if the approved indication is narrower. GLP-2 represents the clearest example of what peptide-driven intestinal healing looks like when it has been put through the rigor of large human trials, and understanding it is useful for calibrating how thin the human evidence base is for most other compounds on this list.

In practice, GLP-2 is not the compound most people are discussing in community leaky gut protocols. It requires a prescription, is expensive, and its approved use case is a more severe clinical condition than the intestinal permeability most readers are researching. It appears here because GLP-2 regularly shows up in the evidence comparisons that practitioners and researchers use when evaluating this field, and leaving it off would give the reader a less complete picture of what exists.

5. GHK-Cu: For Connective Tissue Support Alongside Repair

GHK-Cu is a copper-binding tripeptide that occurs naturally in human plasma, saliva, and urine, with concentrations declining significantly with age. It is primarily associated in the peptide community with skin repair and anti-aging applications, but it shows up consistently in leaky gut protocols because of the connective tissue and collagen dimension of gut barrier healing.

The gut wall is not purely a matter of tight junctions and immune signaling. It also involves the extracellular matrix, the structural scaffolding of connective tissue that the epithelial lining sits on top of. GHK-Cu stimulates collagen synthesis and promotes regenerative processes in damaged tissue, and it carries anti-inflammatory properties that are relevant when barrier damage is accompanied by ongoing tissue degradation. In this context, it is less of a primary gut-healing compound and more of a structural companion, one that addresses the connective tissue layer of the repair job while BPC-157 handles the mucosal and tight junction dimensions.

GHK-Cu does not have published human clinical trial data for leaky gut or intestinal permeability. Its presence in gut protocols is grounded in its well-studied regenerative and collagen-stimulating mechanisms, applied to the gut context through functional medicine practice and community use. It is commonly described in stacking discussions, where practitioners pair it with BPC-157 for a more comprehensive approach to barrier repair. Someone dealing with leaky gut that has a significant connective tissue component, or who wants to address the full repair picture rather than tight junctions alone, is the profile most likely to see GHK-Cu included in a recommended approach.

6. TB-500: For Systemic Tissue Repair as an Adjunct

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide found throughout the body with a particular role in cell migration, tissue regeneration, and the regulation of actin, which is the structural protein that gives cells their shape and motility. It is primarily known in the peptide community for musculoskeletal injury recovery, but it appears in leaky gut discussions as an adjunct compound for its systemic healing effects.

The case for TB-500 in gut repair is indirect. It does not target tight junctions, does not inhibit zonulin, and does not concentrate in bowel tissue the way KPV does. What it does is promote faster tissue regeneration broadly, reduce fibrosis, and support cell migration toward damaged areas, all of which are relevant when the gut wall has sustained significant damage. Animal studies and early community-reported use point toward a role in faster healing of gastrointestinal tissue, and it is used in comprehensive protocols when practitioners want systemic support running alongside more gut-specific compounds.

The evidence for TB-500 in gut applications is thin by clinical standards. What exists is animal data and user-reported experience from community protocols, neither of which constitutes a published human trial for this use. TB-500 is also banned by the World Anti-Doping Agency, which eliminates it as an option for competitive athletes. Its position on this list reflects that it is a real part of the conversation for leaky gut, particularly in stacking protocols, but it functions as an adjunct rather than a primary compound, and its evidence for gut-specific benefit is less developed than anything ranked above it.

7. LL-37: For Leaky Gut Driven by Microbial Imbalance

LL-37 is a human cathelicidin, an antimicrobial peptide produced naturally by immune cells, epithelial cells, and other tissues as part of the body's first-line defense against infection. It is the most niche compound on this list in terms of its leaky gut use case, which is also what makes it worth including: when microbial imbalance is the primary driver of intestinal hyperpermeability, LL-37 addresses a root cause that none of the other compounds here target directly.

The logic starts with what drives leaky gut in cases involving dysbiosis or chronic microbial overgrowth. Bacterial and fungal imbalances in the gut generate ongoing inflammatory signals, degrade the mucosal layer, and sustain the conditions that keep tight junctions from healing. LL-37's antimicrobial activity disrupts pathogenic microbes directly, and its ability to modulate the gut microbiota changes the environment the gut wall is trying to heal in. Users and practitioners who reach for LL-37 in a leaky gut context are typically addressing cases where SIBO, chronic gut infections, or persistent dysbiosis are a documented part of the picture, not cases where the permeability is primarily structural or inflammatory in origin.

No published human clinical trial has examined LL-37 specifically for leaky gut or intestinal permeability as of 2026. Its use in this context is community-reported and practitioner-informed, drawing on its known antimicrobial and immune-modulating properties rather than gut-specific trial data. For a specific subset of people with a microbial presentation, it may be the most relevant option on this list.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for leaky gut?

Only one compound on this list carries FDA approval: GLP-2 in the form of teduglutide, and that approval covers short bowel syndrome rather than leaky gut or intestinal hyperpermeability as those terms are commonly used. Every other compound here is either investigational, approved only in other countries, or a research compound accessed through compounding pharmacies or the research-chemical market. That is the accurate regulatory picture as of 2026.

How do people typically access these peptides?

Access varies by compound. GLP-2 requires a standard prescription. BPC-157, KPV, and GHK-Cu are commonly obtained through telemedicine providers who work with compounding pharmacies, where they are prepared under medical supervision. Larazotide has a more limited access pathway and is sometimes described by practitioners as a compound awaiting broader clinical availability. TB-500 and LL-37 are available through the research-chemical market, though that route lacks the quality controls of a regulated compounding pharmacy. The safest path for any of these is a conversation with a qualified healthcare provider who can assess your situation and route through a licensed pharmacy where appropriate.

Is BPC-157 actually effective taken orally, or does stomach acid break it down?

BPC-157 is one of the very few peptides that is genuinely stable in gastric acid, which is why oral administration is considered a viable and often preferred route for gut-specific applications. Most peptides are broken down in the stomach before they reach the intestinal lining, but BPC-157 survives that environment and can exert a direct local effect on the tissue it is meant to repair. That stability is one of the main reasons it occupies such a central place in the leaky gut conversation: it can be taken in capsule form and still work at the site of the problem.

Do these peptides work better when combined?

The most common approach in functional medicine practices using peptides for leaky gut is to pair a repair-focused compound with an anti-inflammatory one, most often BPC-157 and KPV together, because they address different parts of the same problem. BPC-157 handles the structural work of rebuilding the barrier; KPV quiets the immune overactivation that would otherwise keep damaging it. Whether that combination is appropriate for any individual depends on what is actually driving their permeability, which is why a practitioner assessment matters before layering multiple compounds.

How long does it typically take to notice results?

The timeline varies considerably across compounds and individuals, and no clinical data establishes a reliable expected window for most of these peptides in leaky gut specifically. Community-reported experience with BPC-157 ranges from noticeable improvement within days to several weeks to no effect at all. Nearly every positive report in community discussions is paired with meaningful dietary changes, such as eliminating gluten or dairy, which makes it difficult to attribute improvement to the peptide alone. Treating any specific timeline as a promise would misrepresent what the evidence actually shows.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for leaky gut in one place.